Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) Chief Science Officer Rob Roscow tells Proactive that it has filed a full patent application covering multiple families of psilocin analogs. The Denver-based biotech company said that the application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in medical settings.
Mydecine Innovations talks through recent psilocin analogs, nanoemulsion tech patent applications
